Adelene Perkins, CEO of Infinity Pharmaceuticals Inc., told BioWorld Today that her firm's "going-in assumption is that we will be successful" in selling rights to PI3K inhibitor duvelisib despite Abbvie Inc.'s pullout from their partnership, which followed Gilead Sciences Inc.'s trial-death woes related to Zydelig in the same class and put the jitters into investors even as they hold out hope from the promising approach.